Wednesday, 27 February 2013

Mesothelioma UK acknowledges Prof's treatment.

I was pleased to see Prof Vogl's treatment being talked about in the Mesothelioma UK newsletter, Spring 2013 edition.
Dr Jeremy Steele is at Barts and one of the leading Mesothelioma Dr's in the UK. He hasn't said yes or no to supporting the treatment as we all know it needs to be trialled first. 

What I like is that it is being talked about. i hope this gets out in the big wide world and is considered as another option for mesothelioma patients as there are so very few around. Dr Sugarbaker pioneered a treatment for peritoneal mesothelioma which was talked about at the mesothelioma UK confeence last year. Dr Sugarbaker's treatment was given the same consideration years ago but it now being recognised. So, there maybe hope that someone, somewhere will listen and want to trial chemoperfusion with conventional chemo. The article is below.

An article written by Dr Jeremy Steele at Barts, London.
Published in the latest Mesothelioma UK newsletter, Spring 2013.

Nonselective Transarterial Chemoperfusion: A Palliative Treatment for 
Pleural Mesothelioma. By T Vogl, S Lindemayr, N Naguib, J Gurung, N 
Nour-Eldin, S Zangos, E Mbalisike. Goethe University, Frankfurt, Germany 

Over several years Professor Thomas Vogl and his team 
in Frankfurt have been treating patients with pleural mesothelioma with a technique called ‘Nonselective Transarterial Chemoperfusion’. This is a new way of
delivering cytotoxic chemotherapy to patients with pleural mesothelioma. It is an extension of similar techniques used
in the treatment of cancers in other parts of the body, notably the liver.
Techniques similar to that described in this article are in use in the NHS in the UK, but not for patients with
mesothelioma. Professor Vogl’s technique has been the subject of interest in the UK, especially from patients with mesothelioma who, understandably, want to hear about
all possible treatments. Doctors and nurses caring for people with mesothelioma have also been interested to hear more about this treatment. British doctors have had to be cautious about recommending treatment with nonselectivetransarterial chemoperfusion to patients because no full results for patients with mesothelioma have been available until now.
Professor Vogl’s team have now presented results on 39 patients treated with transarterial chemoperfusion.
The median survival time from first
treatment was 17 months, with a mean
progression-free survival time of 2.6
months (i.e. 79 days). Progression-
free survival is a key measure in a trial
of this type as it is sometimes used
to determine the likely benefit of a
treatment.
By comparison, the progression-free survival in the clinical trial of Pemetrexed and Cisplatin for previously untreated
patients (published in the Journal of
Clinical Oncology by Vogelzang, 2003)
was 5.7 months. An even closer comparison is with
patients treated with Pemetrexed and Cisplatin as second-line chemotherapy (as in Vogl’s trial). According to the
results, these patients had a median survival time of 15.3 months (Manegold,
Annals of Oncology, 2005). And in the randomised ‘MARS’ trial conducted in the UK, the median survival for patients not treated with radical surgery (i.e. with intravenous chemotherapy only)
was 19.5 months (Treasure, Lancet Oncology, 2011).
Professor Vogl and team say the following about transarterial chemoperfusion: ‘This procedure could be of benefit in the treatment of this tumour in stages when it is
unresectable’ and, ‘that our study results will open up the horizon for more studies to be performed.’ Professor Vogl concludes that transarterial chemoperfusion may have the potential to yield positive results and response
in the treatment of recurrent and/or unresectable pleural mesothelioma.
What needs to be done is a randomised trial of transarterial chemoperfusion versus intravenous chemotherapy.
Only a randomised trial can show if transarterial chemoperfusion offers any benefits to patients above and beyond what we can already do. The results presented in the recent article cannot confirm or deny such a benefit.

Consultant Medical Oncologist Barts and the London NHS Trust
Nonselective Transarterial Chemoperfusion: A Palliative Treatment for
Pleural Mesothelioma. By T Vogl, S Lindemayr, N Naguib, J Gurung, N 
Nour-Eldin, S Zangos, E Mbalisike. Goethe University, Frankfurt, Germany


ANTI-E card


I received this in the post yesterday. Because i have had blood transfusions i now have an anti body in my system. this was mentioned when I was cross matched a couple of weeks ago when I had my last transfusion. On the second bag of blood i had a reaction, a high temperature and the shakes (rigours).

It is only since then that I have had problems with allergic reactions with the anti-biotics in hospital. I am wondering if the 2 are connected?
i spoke to the consultant today who said the card is only for when I have a transfusion. I am waiting to see an immunologist, I have told the consultant that as my condition is so serious, I can't wait on a waiting list and am happy to go private if it is quicker. I can't do anything else now until I know what is happening as i was planning more chemo. This has been put on hold for the moment.





The British Lung foundation has a survey on it's web page for mesothelioma patients and families. 

http://www.smart-survey.co.uk/v.asp?i=72322wkgrd


Please copy and paste the link and fill in the survey, thanks for your support.

No comments: